摘要
目的改进抗结核药地依麦迪的合成工艺。方法 2-甲基烯丙醇经Sharpless环氧化后与对硝基苯磺酰氯反应得到中间体(R)-2-甲基环氧丙醇-4-硝基苯甲磺酸酯;N-Boc-4-羟基哌啶与对三氟甲氧基苯酚经Mitsunobu反应、脱保护、Buchwald-Hartwig反应、脱苄基得到中间体4-[4-(4-三氟甲氧基-苯氧基)哌啶基]苯酚,这两个中间体经亲核取代反应得到(R)-1-[4-(2,3-环氧-2-甲基丙氧基)苯基]-4-(4-三氟甲氧基苯氧基)哌啶,该化合物与2-溴-4-硝基咪唑经亲核取代、环合得到终产物地依麦迪。结果与结论工艺优化后,以2-甲基烯丙醇计,总收率为27.6%(优化前为17.8%),以N-Boc-4-羟基哌啶计,总收率为33.4%(优化前为11.0%),产物的HPLC化学纯度为100%,ee值也达到了100%,新工艺路线操作简单,适合工业化生产。
An optimized synthetic process to delamanid was developed. (R) -4-Nitrobenzene sulfonic acid 2-rneth- ylglycidyl (15) was prepared from 2-methallyl alcohol through Sharpless asymmetric epoxidation followed by the hydroxyl group activation with p-nitrobenzenesulfonyl chloride. 4-[ 4-(4-Trifluoromethoxyphenoxy )-piperidin-1- yll phenol(3) was synthesized from N-Boc-4-hydroxyl piperidine and p-trifluoromethoxy phenol via Mitsunobu reaction,Boc deprotection,Buchwald-Hartwig amination and benzyl deprotection. The nucleophilic substitution of 15 with 3 gave ( R )-1-(4-( ( 2-methyloxiran-2-yl ) methoxy ) phenyl )-4-(4-( trifluoromethoxy ) phenoxy ) piperi- dine,which reacted with 2-bromo-4-nitroimidazole to form the desired product(delamanid). The total yield of the process was 27.6% (based on 2-methallyl alcohol) and 33.4% ( based on N-Boc-4-hydroxyl piperidine) respectively,and the HPLC purity and ee value both reached 100%. The optimized synthetic route to delamanid was characterized with improved yield,easier operations,suitable for industrial production.
出处
《中国药物化学杂志》
CAS
CSCD
2017年第3期205-209,共5页
Chinese Journal of Medicinal Chemistry
关键词
地依麦迪
合成
抗结核药
耐多药肺结核病
delamanid
synthesis
antituberculous drug
multidrug-resistant tuberculosis